Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients.
Coiffier
B
B
Hospices Civils de Lyon, France. coiffier@hematologie.univ-lyon1.fr
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D016499:Radioimmunotherapy / Q000009:adverse effects; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000922:Immunotoxins; D000069283:Rituximab